Drugs / IL-15 enhanced engineered NK cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07621471 | Jul 2026 → Dec 2028 expected | metastatic malignant neoplasm | Genovn Therapeutics PTE. LTD. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IL-15 enhanced engineered NK cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07621471 ↗ |
| Modality | Cell therapy | “Genetically engineered NK cells expressing IL-15” NCT07621471 ↗ |
| Route | Intravenous | “Administered intravenously” NCT07621471 ↗ |